$2.22
1.49% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
NL0015000DX5
Symbol
ATAI
Sector
Industry

ATAI Life Sciences N.V. Stock price

$2.25
+0.47 26.40% 1M
+0.90 66.67% 6M
+0.92 69.17% YTD
+0.51 29.31% 1Y
-2.88 56.14% 3Y
-17.20 88.43% 5Y
-17.20 88.43% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.40 21.62%
ISIN
NL0015000DX5
Symbol
ATAI
Sector
Industry

Key metrics

Market capitalization $377.55m
Enterprise Value $301.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 912.24
P/S ratio (TTM) P/S ratio 1,144.09
P/B ratio (TTM) P/B ratio 2.59
Revenue growth (TTM) Revenue growth -0.90%
Revenue (TTM) Revenue $330.00k
EBIT (operating result TTM) EBIT $-105.88m
Free Cash Flow (TTM) Free Cash Flow $-79.86m
Cash position $100.92m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 728.86
EV/Sales forward 581.16
Short interest 9.01%
Show more

Is ATAI Life Sciences N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

ATAI Life Sciences N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ATAI Life Sciences N.V. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a ATAI Life Sciences N.V. forecast:

Buy
100%

Financial data from ATAI Life Sciences N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.33 0.33
0% 0%
100%
- Direct Costs 0.35 0.35
29% 29%
106%
-0.02 -0.02
88% 88%
-6%
- Selling and Administrative Expenses 55 55
7% 7%
16,724%
- Research and Development Expense 50 50
28% 28%
15,248%
-106 -106
18% 18%
-31,979%
- Depreciation and Amortization 0.35 0.35
29% 29%
106%
EBIT (Operating Income) EBIT -106 -106
18% 18%
-32,084%
Net Profit -129 -129
92% 92%
-38,970%

In millions USD.

Don't miss a Thing! We will send you all news about ATAI Life Sciences N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ATAI Life Sciences N.V. Stock News

Positive
Proactive Investors
2 days ago
Positive data from Irish biotechnology firm GH Research's Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT), in treatment-resistant depression bodes well for atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' own psychedelic, analysts at Jefferies believe. Jefferies repeated its ‘Buy' rating on atai and awarded it a $5 price target.
Positive
Seeking Alpha
7 days ago
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results from the phase 2b study using BPL-003 for treatment-resistant depression expected in mid-2025. The global treatment-resistant depression treatment market is projected to reach $4.06 billion by 2030.
Positive
Proactive Investors
8 days ago
atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for psychedelic drug candidates over the next 12 to 18 months, analysts at Jefferies believe. “Seeing positive data could strengthen the notion psychedelics have an important role for hard-to-treat $1 billion-plus central nervous systems disorders, as well as reassure investors the FDA's reject...
More ATAI Life Sciences N.V. News

Company Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Head office Netherlands
CEO Srinivas Rao
Employees 83
Founded 2018
Website www.atai.life

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today